X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TT11 is an autologous CD30 chimeric antigen receptor T-cell (CAR-T) therapy that harvests the patient’s own T-cells and modifies them to target cancer cells expressing the CD30 protein, a well-validated lymphoma target.
Lead Product(s): TT11X,Nivolumab,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: TT11X
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 16, 2023
Details:
Under terms of the CRADA, Tessa will collaborate with the NCI’s DCTD to identify potential opportunities to expand the applicability of TT11X, Tessa’s allogeneic off-the-shelf CD30.CAR-modified EBVST cell therapy, as a treatment of non-Hodgkin lymphoma.
Lead Product(s): TT11X
Therapeutic Area: Oncology Product Name: TT11X
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 08, 2023
Details:
The results demonstrated TT11 to be well-tolerated with promising efficacy in relapsed or refractory (r/r) CD30-positive classical Hodgkin lymphoma (cHL). The CD30.CAR-T cell therapy was demonstrated to be well tolerated with no unexpected safety signals.
Lead Product(s): CD30.CAR-T,Fludarabine Phosphate,Bendamustine Hydrochloride
Therapeutic Area: Oncology Product Name: TT11
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2022
Details:
TT11X (CD30.CAR-EBVST cells) utilizes CD30.CAR-modified Allogeneic Epstein-Barr Virus Specific T-Cell (EBVST) to target relapsed or refractory CD30-positive lymphomas.
Lead Product(s): CD30.CAR-EBVST Cells
Therapeutic Area: Oncology Product Name: TT11X
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Baylor College of Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 07, 2022
Details:
TT11X, Tessa’s allogeneic “off-the-shelf” cell therapy, is based on Tessa’s proprietary CD30.CAR-modified Epstein-Barr virus-specific T-cell (EBVST) platform.
Lead Product(s): TT11X
Therapeutic Area: Oncology Product Name: TT11X
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
TT11 is an autologous CD30 chimeric antigen receptor T-cell (CAR-T) therapy that harvests the patient’s own T-cells and modifies them to target cancer cells expressing the CD30 protein, a well-validated lymphoma target.
Lead Product(s): Autologous CD30.CAR-T Cell Therapy,Nivolumab,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: TT11
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 17, 2022
Details:
TT11 – is an autologous CD30 targeting CAR-T therapy currently being investigated as a potential treatment for relapsed or refractory classical Hodgkin lymphoma.
Lead Product(s): CD30.CAR-T,Fludarabine Phosphate,Bendamustine Hydrochloride
Therapeutic Area: Oncology Product Name: TT11
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 13, 2022
Details:
Tessa plans to use the proceeds from the financing to advance the ongoing clinical development of the company’s autologous CD30-CAR-T therapy (TT11) and allogeneic CD30.CAR EBVST therapy (TT11X) programs.
Lead Product(s): CD30.CAR-T,Fludarabine Phosphate,Bendamustine Hydrochloride
Therapeutic Area: Oncology Product Name: TT11
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Polaris Partners
Deal Size: $126.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing June 09, 2022
Details:
The PRIME designation was granted to TT11 by EMA on the back of promising clinical data from two Phase I/II trials in R/R cHL conducted at Baylor College of Medicine and University of North Carolina Lineberger Comprehensive Cancer Center.
Lead Product(s): CD30.CAR-T,Fludarabine Phosphate,Bendamustine Hydrochloride
Therapeutic Area: Oncology Product Name: TT11
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2021
Details:
The designation is based on the data of two independent Phase I/II trials, which show promising efficacy and strong safety profile of the therapy in Hodgkin lymphoma patients.
Lead Product(s): CD30 CAR-T
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
